Researchers at the University of Southern California report that a small, largely forgotten thymus hormone called thymulin acts as a brake on the chronic, low-grade inflammation that builds up with age. As the thymus shrinks over a lifetime, thymulin disappears from the blood, and inflammatory myeloid immune cells run unchecked, spewing cytokines that help tumors grow and blunt the response to immunotherapy. Giving thymulin back to old mice quieted these inflammatory cells, slowed breast tumor growth, boosted anti-tumor T cells, and, most notably, restored the ability of an otherwise useless checkpoint drug to work. The effect was seen only in aged animals, not young ones, suggesting thymulin restores something age has removed rather than supercharging a healthy immune system.
One of the quieter tragedies of getting older is that the immune system starts working against itself. Instead of standing guard, it simmers. This slow, sterile, system-wide inflammation, known as inflammaging, is now linked to almost every disease of later life, from heart disease and dementia to cancer. What has been missing is a clear culprit and, better still, something that could be given back.
A team at the Keck School of Medicine of USC, led by Fumito Ito, thinks it has found one. Working in mice and human blood samples, the group first confirmed that a specific set of immune cells, the myeloid cells that include monocytes, macrophages, and granulocytes, become far more inflammatory with age. In old mice, the fraction of these blood cells pumping out inflammatory signals such as IL-1, IL-6, and TNF rose several-fold compared with young animals, and the same pattern showed up in older human donors and in human breast tumors.
The clever part came next. The researchers surgically joined young and old mice so they shared a bloodstream, a technique called parabiosis, and separately swapped their bone marrow. The inflammation in old immune cells calmed down when they were bathed in young blood, and it did so even when the immune cells themselves stayed old. That pointed to a circulating factor coming from somewhere other than the bone marrow. A computational hunt through aging pathways kept flagging the thymus, the small gland behind the breastbone that trains T cells and famously withers after childhood.
The suspect they landed on was thymulin, a nine-amino-acid zinc-dependent peptide the thymus secretes, whose blood levels fall to near zero in old age. When the team gave thymulin to old mice, their inflammatory myeloid cells settled down, breast tumors grew more slowly, and survival improved. Thymulin worked by blocking NF-kB, a master switch for inflammatory genes. The headline result for cancer medicine: old mice normally ignore anti-PD-L1 checkpoint therapy, but adding thymulin made their tumors respond.
Two cautions temper the excitement. This is a mouse and cell study, and the survival data track tumor-bearing animals rather than natural lifespan, so nothing here yet speaks to human aging directly. Still, it reframes the shrinking thymus not as a passive casualty of age but as an active regulator whose decline may help cancer take hold.
Actionable Insights
There is no consumer-ready intervention here, and the practical value is directional. First, the magnitude of the age effect is large: in mouse blood the share of myeloid cells producing IL-1beta rose from roughly 1.0 percent in young to 11.2 percent in aged, an increase of about 11-fold; IL-1alpha rose from 2.6 to 16.2 percent (about 6-fold); IL-6 from 7.0 to 22.2 percent (about 3-fold); and TNF-alpha from 11.1 to 28.8 percent (about 2.6-fold). Human data mirror the direction, with cytokine-positive myeloid frequency correlating positively with age across 90 donors.
The mechanistic takeaway that generalizes to lifestyle is that NF-kB-driven myeloid inflammation is a plausible, measurable lever on both cancer risk and immunotherapy response. Interventions already known to lower IL-6, IL-1, and TNF or to support thymic function (managing visceral adiposity, resistance and aerobic exercise, adequate zinc status given thymulin is zinc-dependent, and sleep) are directionally consistent with this biology, though this paper tests none of them.
Context and Source
- Open access Paper: Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy.
- Authors and institution: Hisashi Kanemaru, Steven Luong, Yuta Yamamoto, Yukari Mizukami, and Fumito Ito; Department of Surgery and Department of Immunology and Immune Therapeutics, Keck School of Medicine of the University of Southern California, Los Angeles, USA.
- Country: United States.
- Journal: Nature Communications (2026, volume 17, article 6534)
- Impact evaluation: The impact score of this journal is 18.1 (2025 Journal Impact Factor, released June 2026; CiteScore 24.8), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.